Summary
In the late 1990s, the identification of transporters and transporter-associated genes progressed substantially due to the development of new cloning approaches such as expression cloning and, subsequently, to the implementation of the human genome project. Since then, the role of many transporter genes in human diseases has been elucidated. In this overview, we focus on inherited disorders of epithelial transporters. In particular, we review genetic defects of the genes encoding glucose transporters (SLC2 and SLC5 families) and amino acid transporters (SLC1, SLC3, SLC6 and SLC7 families). 
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Introduction
The human genome contains approximately 2000 genes encoding membrane transporters and transporter-associated proteins (Landowski et al 2005) . Transporters are integral proteins that play crucial physiological roles by participation, for example, in cellular nutrition and by regulating ionic, osmotic and acid-base homeostasis. They accomplish these important tasks by promoting the cellular or organellar uptake or efflux of vital substances such as sugars, amino acids, nucleotides, Krebs cycle intermediates, vitamins, organic and inorganic ions, urea, metals, water and drugs. Transporters can be divided into three classes: channels, ATP-dependent transporters and solute carrier (SLC) proteins. (1) Channels are pore-forming structures that allow the passive translocation of ions, water or other solutes along their electrochemical gradients across membranes. Ion channels often include Fgates_ that can be opened or closed through diverse gating mechanisms. (2) In higher organisms, ATPdriven transporters allow the active cellular exit of solutes. Because these transporters use ATP hydrolysis as a primary energy source to drive active transport, they are termed primary-active transporters or pumps. ATP-binding cassette (ABC) transporters (such as the MDR multidrug resistance transporters) are ATPdependent transporters that mediate the cellular exit of solutes. (3) The SLC families include the classical carrier proteins that transport solutes in a passive or secondary active mode (Hediger et al 2004) . These transporters undergo sequential conformational changes during the transport cycle. SLC proteins include facilitated transporters that mediate the diffusion of solutes such as glucose, amino acids and urea across membranes down their electrochemical gradients ( Fig. 1) . SLC proteins can also transport more than one substrate simultaneously, with fixed coupling stoichiometries. Coupling of the transport of solutes to the cotransport of Na + or H + allows uphill solute transport against an electrochemical gradient (see Fig. 1 ). Such transporters are called secondary-active transporters. Examples are the intestinal Na + /glucose cotransporter (SLC5A1) or the intestinal H + -oligopeptide transporter (SLC15A1). In general, secondaryactive transporters use the electrochemical gradients of ions generated by pumps (especially the ubiquitous Na + ,K + -ATPase or the H + V-ATPase) to maintain the cellular homeostasis. The SLC proteins also encode a variety of antiporters or exchangers (transporters of substrates in opposite directions) and multiporters (transporters of substrates in both directions, Fig. 1 ).
The FHUGO Gene Nomenclature Committee_ (HGNC; http://www.genenames.org/) database includes over 45 SLC superfamilies which include a total number of almost 400 transporter genes. A website has been established (http://www.bioparadigms.org/SLC/menu.asp) that gives the latest updates on the SLC superfamilies and members, including their roles in human diseases. In general, these genes are numbered numerically using the root abbreviation SLC (e.g., SLC1, solute carrier family 1), followed by the letter FA_ (used solely as a spacer) and the number of the individual transporter (e.g., SLC1A2 for solute carrier family 1 member 2). A transporter is assigned to a specific family if it shows at least 15-25% amino acid sequence identity with the other members of that family. Although most of the SLC proteins are now cloned and functionally well characterized, a number of them are still Forphans_ because their transport function remains unknown.
SLC proteins are expressed in the plasma membranes or in membranes of intracellular compartments such as vesicles, lysosomes and mitochondria. Numerous inherited or acquired human diseases are caused by SLC protein dysfunction. To this end, the Online Mendelian Inheritance in Man (OMIM) web site (http://www.ncbi.nlm.nih.gov/sites/entrez/) lists all of the human inherited disease found to date and their related gene mutations SLC-related inborn errors of metabolism (IEMs) can be caused by mutations in the transporter genes themselves or in genes encoding regulatory components of the transporters such as enzymes or cytoskeleton proteins (Gamba 2005; Ikeda et al 2006) .
There are several molecular mechanisms by which mutations can alter transporter activities with subsequent pathological consequences. Mutations can alter the membrane expression of transporters through changes in protein synthesis or protein processing, Fig. 1 Transport types of the SLC carriers through altered membrane targeting or membrane insertion, or through direct changes in the functional properties of the protein. SLC proteins may also be involved in polygenic or acquired diseases such as epilepsy, osteoporosis, nephrolithiasis, diabetes, cancer and hypertension, for which the precise mechanism of pathogenesis is still unclear. Genetic approaches such as the identification of single nucleotide polymorphisms (SNPs), genotyping and transgenic strategies have been helpful in revealing the involvement of SLC proteins in human physiology and in elucidating their roles in human diseases. Clinical, molecular and functional studies are still required to confirm many of these findings.
Glucose transport
Glucose is essential for cellular metabolism and energy production. Transporters of glucose and related sugars are encoded by two SLC gene families: the SLC2 family of facilitated glucose transporters (also called GLUTs), and the SLC5 family of Na + -coupled glucose cotransporters (also called SGLTs). Owing to their importance in human physiology, it is not surprising that each of these SLC families is associated with human diseases.
Inborn errors of the SLC2 gene family
The SLC2 family contains 14 members: 12 facilitated glucose transporters (SLC2A1-12 or GLUT1-12), one fructose transporter (SLC2A5 or GLUT5) and one myo-inositol transporter (SLC2A13 or GLUT13). All SLC2 genes encode transporters possessing 12 membrane-spanning domains, with N-and C-termini being localized intracellularly. Tissue-and cell-specific expression of the GLUT homologues underlies their specific role in the control of whole-body glucose homeostasis, which is supported by studies with transgenic mice (Heilig et al 2003) . Inherited diseases are particularly linked to mutations encoding the GLUT1, GLUT2, GLUT4 and GLUT10 transporters.
In 1985, GLUT1 was the first transporter of this family to be cloned (Mueckler et al 1985) . This protein is a high-affinity glucose transporter distributed in almost every tissue, although expression levels vary within different cell types. For example, GLUT1 is highly expressed in endothelial cells at the blood-brain barrier, where it constitutes an important glucose entry pathway into the brain (Agus et al 1997) . The first defect in an SLC2 transporter was demonstrated by DeVivo et al (1991) , who reported two SLC2A1-deficient patients with infantile seizures, delayed development and acquired microcephaly. These symptoms are consistent with a defect in glucose transport across the blood-brain barrier (OMIM 606777 in Table 1 ). In 2000, the designation FGLUT1 deficiency syndrome_ was used for the same disorder observed in 15 children in which heterozygous mutations in the SLC2A1/GLUT1 gene were found (Wang et al 2000) . This transport disorder has an autosomal dominant transmission mode. To date, several mutations in the SLC2A1 gene were found to cause defects in glucose transport across the blood-brain barrier. Deletions, insertions, missense or nonsense mutations were identified in affected patients (Brockmann et al 2001; DeVivo et al 1991; Klepper et al 2001; Seidner et al 1998; Wang et al 2000) . One of them, the p.Gly91Asp substitution, has been further studied functionally (Klepper et al 2001) . This amino acid exchange affects a highly conserved cytoplasmic anchor point, the socalled R-X-G-R-R motif between helices 2 and 3. The GLUT1 protein expression at the plasma membrane was unchanged by this mutation, but was functionally impaired.
The SLC2A2 gene encodes the facilitated glucose transporter GLUT2. It was isolated from adult human liver and kidney cDNA libraries and was found to have 55.5% identity with GLUT1. The encoded protein is particularly distributed in intestine, kidney, liver and pancreas: tissues known to have high-capacity glucose transport systems (Fukumoto et al 1988) . GLUT2 is present in the basolateral membrane of absorptive epithelial cells where it participates in the transepithelial transport of glucose, together with the apical Na + -glucose cotransporters SLC5A1 or SLC5A2 (described below). In hepatocytes, GLUT2 is localized in the sinusoidal membrane where it controls the cellular uptake and efflux of glucose into the circulation. In the insulin-producing b-cells of the pancreas, GLUT2 resides in specific plasma membrane domains (Orci et al 1989) . Functionally, GLUT2 facilitates the transport of glucose, galactose, mannose and fructose with low affinity and high capacity.
The defect of this protein is linked to several human diseases. The first mutation found in the SLC2A2 gene was an amino acid substitution (p.Val197Ile), present in the heterozygous state in a patient with non-insulindependent diabetes mellitus (Mueckler et al 1994; Tanizawa et al 1994) . Functional characterization of this mutation in Xenopus oocytes showed abolition of GLUT2 transport activity. However, it is still unclear whether the heterozygosity for this mutation is of clinical relevance or was just an incidental finding in this individual. The other known human disease caused by a GLUT2 defect is the Fanconi-Bickel syndrome (OMIM 227810 in Table 1 ) which is inherited in an autosomal recessive mode. It is mainly characterized by hepatorenal glycogen accumulation, proximal renal tubular dysfunction and impaired utilization of glucose and galactose (Manz et al 1987) . At least 30 mutations in the SLC2A2 gene have been reported to be causes of this disease. An interesting example is presented by a deletion mutation generating a premature TGA stop codon at position 74 (g.446-449delT, p.Met74X) (Santer et al 1997) . It was found to encode one of the shortest truncated GLUT2 proteins. Some nonsense mutations, substitutions or splice acceptor sites were also found in different patients affected with this disease (Akagi et al 2000; Sakamoto et al 2000; Sanjad et al 1993; Santer et al 1997 Santer et al , 2002 .
Another facilitated glucose transporter known to be linked to a human inherited disease is GLUT10, encoded by the SLC2A10 gene. This gene was cloned from a human liver cDNA library (McVie-Wylie et al 2001) . GLUT10 is expressed in many human tissues and organs such as heart, lung, brain, liver, skeletal muscle, pancreas, placenta, kidney and adipose tissue (McVie-Wylie et al 2001; Wood et al 2003) . GLUT10 was first suggested to be a candidate susceptibility gene for non-insulin-dependent diabetes mellitus (McVie-Wylie et al 2001) . However, Coucke et al reported the mapping of the arterial tortuosity syndrome (ATS) to the 20q13 locus where SLC2A10 is located (Coucke et al 2003) . ATS is a rare autosomal recessive connective-tissue disorder, characterized by widespread arterial involvement with elongation, tortuosity, stenosis and aneurysms of the large and middle-sized arteries (OMIM 208050 in Table 1 ). The pathogenesis of ATS seems to be due to the upregulation of the TGFb signalling pathway (Coucke et al 2006) . However, the mechanisms by which mutations in the SLC2A10 gene lead to TGFb activation are still unknown.
Inborn errors of the SLC5 gene family
The second family of mammalian glucose transporters is the FSLC5 Na + /glucose cotransporter family_. The first reported member of this family is the Na + /glucose cotransporter 1 (SGLT1) encoded by the SLC5A1 gene. It was identified by expression cloning with Xenopus oocytes (Hediger et al 1987) . There are 11 gene members in this SLC5 family. Most of them function as Na + -coupled substrate transporters. Transported substrates include glucose, myo-inositol, mannose, vitamins, monocarboxylates and iodide (Agus et al 1997; Kanai et al 1994; Roll et al 2002; Smanik et al 1997; Srinivas et al 2005; Tazawa et al 2005) . SGLT1 mediates secondary active glucose absorption across brush border membrane of epithelial cells in the intestine. This function explains the phenotype of the inherited disease linked to SGLT1 defects, called glucose/galactose malabsorption (GGM), which is characterized by diarrhoea and dehydration (see OMIM 606824 in Table 1 ). Around 50 mutations were found in patients with GGM (Lam et al 1999; Martin et al 1996; Turk et al 1991 Turk et al , 1994 . The first mutation was demonstrated in two sisters with glucose/galactose malabsorption. It was a G>A transition at nucleotide 92, resulting in an aspartate-to-asparagine substitution at position 28 in the transporter protein (g.92 G>A, p.Asp28Asn) (Turk et al 1991) . Although missense mutations can lead to the synthesis of full-length proteins, these involved in GGM cause defects in trafficking of the proteins to the plasma membrane (Turk et al 1993) . Another group showed that in 15 patients with missense mutations, the function of SLC5A1 was directly impaired (Martin et al 1996) . Nonsense or frameshift mutations result in truncated proteins that are not functional.
The human SLC5A2 (alias SGLT2) was demonstrated to be a kidney-specific transporter. It functions as a low-affinity high-capacity Na + -glucose cotransporter (Kanai et al 1994) . Detailed localization studies demonstrated that SGLT2 is expressed in the apical membranes of S1 and also S2 segments of the proximal tubule (PT) cells. SGLT2 is responsible for reabsortion of the bulk of filtered D-glucose. It does not transport D-galactose. In contrast, intestinal SGLT1 is a highaffinity low-capacity glucose and galactose transporter. In the kidney, SGLT1 is expressed in proximal tubule S3 segments where it reabsorbs any residual glucose which escaped the S1 and S2 segments. Not too surprisingly, it was proposed that a defect in the SGLT2 gene could be involved in the familial form of renal glucosuria (RG; OMIM 233100 in Table 1 ). The clinical symptoms of this autosomal recessive disorder are substantial daily loss of glucose, despite a normal glucose tolerance test. To date, about 26 mutations have been described in patients with RG. In 2002, homozygosity for a nonsense mutation was demonstrated in a patient with RG (van den Heuvel et al 2002). Moreover, other truncating mutations were found in the SLC5A2 gene in patients with RG (Calado et al 2004) . Extensive analysis of RG patients by Santer and collaborators confirmed the important role of the SCL5A2 glucose transporter in renal tubular glucose reabsorption (Santer et al 2003) .
The human sodium/iodide symporter (NIS) which also transports other monovalent anions, is encoded by the fifth member of the SLC5 transporter group (Smanik et al 1996) . The primary function of this transporter is to take up I j from blood across the basolateral membrane of the thyroid follicular cells in order to secrete I j through the SLC26A4 anion exchanger into the follicular lumen, wherein organification of I j occurs that is necessary for the synthesis of the T 3 and T 4 thyroid hormones. The NIS transporter is also expressed in colon, breast and ovary (Smanik et al 1996 (Smanik et al , 1997 . Studies on the regulation of the NIS gene revealed that the NIS gene expression is tightly controlled by the thyroid-stimulating hormone and the thyroid transcription factor and that DNA methylation plays a role in loss of SLC5A5 gene expression in thyroid carcinomas (Ohmori et al 1998; Venkataraman et al 1999) . SLC5A5 gene expression appears to play a key role in thyroid gland function. As expected, the first mutation in the NIS gene was found in a patient with an iodide transport defect in the synthesis of thyroid hormones (OMIM 274400 in Table 1 ). This defect is characterized by an inability of the thyroid to maintain a concentration difference of iodide between the plasma and the thyroid gland. Symptoms of this patient were mild goitre and multiple mass lesions in lobes of the thyroid. The mutation identified was a single A>C transversion which replaced threonine by proline at position 354 (c.1060A>C, p.Thr354Pro) (Fujiwara 1997 ). To date, eight different mutations were found in patients with thyroid hormogenesis defects, including 5 missense mutations, 2 nonsense mutations and 1 deletion mutation (Kosugi et al 1998 (Kosugi et al , 1999 (Kosugi et al , 2002 Pohlenz et al 1998) . These mutations are believed to decrease the SLC5A5 transport activity at the plasma membrane.
Amino acid transport
Amino acids are required for protein synthesis and they also represent an important source of nitrogen. Some amino acids are considered essential, because cells cannot synthesize them. The liver is the major site of nitrogen metabolism in the body. Amino acids can be divided into three families: those that are glucogenic, those that are ketogenic or those that are both. Amino acids are precursors of the formation of glucose or acetyl-CoA and these two products are essential for ATP production by the Krebs cycle. Another very important role for amino acids is their function as neurotransmitters such as glutamate, aspartate and g-aminobutyrate. The amino acids glutamate and aspartate are excitatory neurotransmitters which are released at glutamatergic synapses of the mammalian central nervous system. An accumulation of extracellular excitatory amino acids can be excitotoxic.
The following SLC gene families are associated with amino acid transporter disorders: the SLC1 family encoding glutamate and neutral amino acid transporters, the SLC3 family encoding the heavy subunits of heteromeric amino acid transporters, the SLC6 family encoding Na + -and Cl j -dependent neurotransmitter transporters, the SLC7 family encoding the cationic amino acid/glycoprotein-associated amino acid transporters, and the SLC25 family encoding mitochondrial transporters. . The membrane topology model of these transporters shows special features in that the central domain possesses 8 transmembrane (TM) segments and 3 reentrant loops, with both amino-and carboxyl-termini in the cytosol (Grunewald and Kanner 2000; Torres and Amara 2007) . Because of the importance of these transporters in neurotransmission, genetic diseases associated with their dysfunction are expected to be rare. Nevertheless, a heterozygous mutation (g.1047C>G, p.Pro290Arg) in the SLC1A3 gene (alias excitatory amino acid transporter 1 or EAAT1) was found in only a single patient with episodic ataxia, seizures, migraine, and alternating hemiplegia (Jen et al 2005) . This mutation was not present in the patient_s asymptomatic parents, suggesting that it arose de novo. Functional studies showed that the missense substitution leads to decrease of both glutamate uptake and EAAT1 expression to plasma membrane, which contributes to neuronal hyperexcitability in the patient (Jen et al 2005) . However, no further information is known about this mutation and its clinical relevance.
Inborn errors of the SLC3 gene family
The family of SLC3 genes consists of two genes, rBAT and 4F2hc, encoding proteins with one single transmembrane domain: a large extracellular glycosylated C-terminus and a short intracellular N-terminus (type II membrane glycoproteins). The proteins of the SLC3 family form the so-called heavy subunits of heteromeric amino acid transporters (HATs). In these transporters, the light subunits, which are members of the SLC7 family (described below), form the actual transporter unit (Wagner et al 2001) .
By expression cloning using Xenopus oocytes, rBAT (related to b 0,+ amino acid transporter) cDNA was identified, which is named SLC3A1. rBAT is expressed in the apical plasma membrane of epithelial cells in kidney and small intestine where it is involved in transport of cystine and dibasic and neutral amino acids (Palacin and Kanai 2004; Wells et al 1992) . Cystinuria is characterized by cystine precipitation inducing the formation of calculi in the urinary tract, which leads to obstruction, infection and finally renal insufficiency (OMIM 220100 in Table 2 ). Cystinuria is a rare disorder which has an autosomal recessive transmission mode (Calonge et al 1995; Garrod and Hurtley 1906; Palacin et al 2001) . In general, the excretion of both cystine and dibasic amino acids is increased in the urine in patients with cystinuria.
Mutations in the SLC3A1 and SLC7A9 genes are responsible for the disease. The disease can be divided into phenotype A (normal amino aciduria in heterozygotes) and phenotype B (moderate to high hyperexcretion of cystine and dibasic amino acids in heterozygotes). Cystinuria type A is caused by mutations in the SLC3A1 gene, whereas mutations in the SLC7A9 gene cause cystinuria type B, in addition to some cases of cystinuria Ftype I_ (Calonge et al 1994 (Calonge et al , 1995 Dello Strologo et al 2002) . In 2002, Dello Strologo et al suggested that this classification system should be replaced by a new one: type A due to mutations in the SLC3A1 gene, type B due to mutations in the SLC7A9 gene, and type A/B due to mutations in both the SLC3A1 and SLC7A9 genes (Dello Strologo et al 2002) . To date, more than 60 mutations in the SLC3A1 gene have been identified, mostly missense mutations (Palacin et al 2001) .
Inborn errors of the SLC7 gene family The SLC7 family corresponds to the cationic amino acid transporters (CAT). They also include the glycoprotein-associated amino acid transporters (gpaAT). The SLC7 family contains 11 genes. This family can be further divided into two functional subgroups, the CAT group (SLC7A1-4) and the gpaAT group (SLC7A5-11), also called light chains of the heterodimeric amino acid transporters HAT (see above) (Deves et al 1998; Kim et al 1991) . In general, CATs function as facilitated transporters, whereas gpaATs mostly function as obligatory exchangers. They also largely differ in their predicted structure, in that the CATs have 14 putative TM segments and are glycosylated, whereas the gpaATs have 12 TM domains, are not glycosylated and need to associate with a glycoprotein of the SLC3 superfamily (4F2hc or rBAT) for surface expression.
Two gpaAT genes were identified as linked to human inherited disease. The first is SLC7A7 and encodes the y + L-type amino acid transporter 1 (y + LAT1) which has been shown to mediate preferentially the exchange of cytosolic cationic amino acid for extracellular neutral amino acid (Torrents et al 1998) . The causal gene in lysinuric protein intolerance (LPI; see OMIM 222700 in Table 2 ) was mapped to the locus 14q11.2 corresponding to the same chromosomal region as the SLC7A7 gene. These results strongly suggest that dysfunction of y + LAT1 is a cause of LPI. Indeed, a defect in the plasma membrane transport of dibasic amino acids was demonstrated at the basolateral membrane of renal tubule epithelial cells, in small intestine and in skin fibroblasts from patients with LPI. LPI is a rare autosomal recessive disease and symptoms of LPI were described as severe mental retardation, physical retardation, mild intestinal malabsorption syndrome and increase in urinary excretion of lysine, ornithine and arginine (Oyanagi et al 1970) . Mutated SLC7A7 proteins were initially found in 31 Finnish patients and 1 Spanish patient with LPI. The Finnish patients were homozygous for a missense mutation leading to a premature stop codon (g.1181A>T, p.Phe308X). This mutation abolishes an acceptor AG splice site at the end of the intron and leads to cryptic splicing at the next AG site, 10 bp downstream. The Spanish patient was a compound heterozygote with a frameshift mutation (g.1291delCTTT) in one allele and a missense mutation (g.1287T>G, p.Lys334Arg) on the other allele (Torrents et al 1999) . To date, about 20 mutations were found in the SLC7A7 gene of patients with LPI.
The other SLC7 gene linked to an inherited disease is SLC7A9 encoding the b 0,+ amino acid transporter. This transporter was found to be expressed in kidney, liver, small intestine and placenta where, in contrast to SLC7A7, it mediates preferentially the exchange of extracellular cationic amino acids for intracellular neutral amino acids (Feliubadalo et al 1999) . As noted above, mutations in this gene were shown to be linked to cystinuria type B. Numerous mutations in the SLC7A9 gene were found in patients with cystinuria (Font et al 2001) . Several members of the SLC6 family are linked to inherited diseases. Many are associated with primarily neurological disorders and are therefore not discussed further in this overview. Defects of SLC6A19 are related to a type of amino aciduria. This gene encodes the system B 0 transporter, called B 0 AT1. High levels of expression of SLC6A19 were found in the apical membrane of renal and small intestinal epithelial cells. Functional studies in Xenopus oocytes showed that the SLC6A19-mediated transport is electrogenic and Na + -and pH-dependent, and that, in contrast to other analogues of the SLC6 superfamily, it is Cl j -independent (Broer et al 2004; Kleta et al 2004) . Using homozygosity mapping, Kleta and collaborators confirmed that the causative gene in the Hartnup disorder is located on locus 5p15 and corresponds to SLC6A19 (Kleta et al 2004) . This disorder is an autosomal recessive disorder which is characterized by a pellagra-like light-sensitive rash, cerebellar ataxia, emotional instability, and amino aciduria (OMIM 234500 in Table 2 ). Ten different mutations have been described to date causing this disease. One mutation, the p.Asp173Asn allele, is present in 42% of Hartnup chromosomes from unrelated families from Australia and North America (Azmanov et al 2007) . These mutations apparently reduce the transport function of neutral amino acids across epithelial cells in renal proximal tubules and intestinal mucosa. Iminoglycinuria is a rare autosomal recessive disorder characterized by increased urinary excretion of proline, hydroxyproline and glycine, resulting in neurosensory hearing loss and ichthyosis, which may be associated with mental retardation (Goyer et al 1968; Swarna et al 2004) . Iminoglycinuria has been suggested to be caused by defects of renal tubule amino acid transporters. The gene product of SLC6A20 (also known as sodium imino acid transporter 1 or SIT1) has been characterized recently (Takanaga et al 2005) . Its functional properties were shown to correspond to those of the classical system IMINO which mediates Na + -dependent proline uptake into epithelial cells of kidney and intestine. It is tempting to speculate that mutations in the SLC6A20 gene are the cause of some cases of hereditary iminoaciduria. However, the precise genetic defects of this disease have not yet been elucidated.
Inborn errors of the SLC25 gene family
Members of the SLC25 family of mitochondrial carriers also transport amino acids, and defects of their genes can be involved in such human pathologies as seizures. One example has been described recently and concerns defects of the SLC25A22 gene, which encodes a ubiquitous glutamate multiporter (transport of l-glutamate either with H + or in exchange for OH j ; see Fig. 1 ) (Fiermonte et al 2002) . Molinari and colleagues found the SLC25A22 gene within the interval on 11p15.5 linked to neonatal myoclonic epilepsy with suppression-burst pattern (OMIM 609304 in Table 2 ). This inherited disease has an autosomal recessive transmission mode and is principally characterized by early-onset severe seizures and neonatal hypotonia. In the same work, Molinari and colleagues reported the identification of a homozygous missense mutation in the SLC25A22 gene (p.Pro206Leu) which causes impaired mitochondrial glutamate transport and consequently seizures in the affected children (Molinari et al 2005) .
